ReviewPathogens (Basel, Switzerland)2016
Deliberate Establishment of Asymptomatic Bacteriuria-A Novel Strategy to Prevent Recurrent UTI.
Review in Pathogens (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- A systematic review of randomised clinical trials for oral antibiotic treatment of acute pyelonephritis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Pooled it
- Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial.Urologia internationalis · 2018Trial
- Evaluation of the Lodestar DX: a comparison with traditional culture for the detection of bacteriuria in the workup of urinary tract infection.JAC-antimicrobial resistance · 2025Article
- Effect of Bladder Catheterization On Bacterial Interference With Asymptomatic Escherichia coli Strain 83972 in an Experimental Porcine Model of Urinary Tract Infection.The Journal of infectious diseases · 2025Article
- Less is more: the lack of autoinducer-2-dependent quorum sensing promotes competitive fitness ofFrontiers in cellular and infection microbiology · 2025Article
- Competitive fitness of asymptomatic bacteriuriaInfection and immunity · 2024Article
- Asymptomatic Bacteriuria in Kidney Transplant Recipients-A Narrative Review.Medicina (Kaunas, Lithuania) · 2023Review
- Phenotypic Assessment of Clinical Escherichia coli Isolates as an Indicator for Uropathogenic Potential.mSystems · 2022Article
- Controlling shape morphing and cell release in engineered living materials.Biomaterials advances · 2022Article
- Multidrug-resistant Uro-associatedEuropean urology open science · 2022Article
- Treatment of Urinary Tract Infections with CanephronAntibiotics (Basel, Switzerland) · 2021Article
- The immune response to infection in the bladder.Nature reviews. Urology · 2020Review
- Defining a Molecular Signature for Uropathogenic versus Urocolonizing Escherichia coli: The Status of the Field and New Clinical Opportunities.Journal of molecular biology · 2020Article
- Asymptomatic bacteriuria in older adults: the most fragile women are prone to long-term colonization.BMC geriatrics · 2019Article
- Frequency of bacteriuria in dogs with chronic kidney disease: A retrospective study of 201 cases.Journal of veterinary internal medicine · 2019Article
- High molecular weight hyaluronic acid: a two-pronged protectant against infection of the urogenital tract?Clinical & translational immunology · 2018Article
- Review
- Targeting Deficiencies in the TLR5 Mediated Vaginal Response to Treat Female Recurrent Urinary Tract Infection.Scientific reports · 2017Article
- How holobionts get sick-toward a unifying scheme of disease.Microbiome · 2017Article
- Inappropriate Management of Asymptomatic Patients With Positive Urine Cultures: A Systematic Review and Meta-analysis.Open forum infectious diseases · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have established a novel strategy to reduce the risk for recurrent urinary tract infection (UTI), where rapidly increasing antibiotic resistance poses a major threat. Epidemiologic studies have demonstrated that asymptomatic bacteriuria (ABU) protects the host against symptomatic infections with more virulent strains. To mimic this protective effect, we deliberately establish ABU in UTI-prone patients, who are refractory to conventional therapy. The patients are inoculated with Escherichia coli (E. coli) 83972, now widely used as a prototype ABU strain. Therapeutic efficacy has been demonstrated in a placebo-controlled trial, supporting the feasibility of using E. coli 83972 as a tool to prevent recurrent UTI and, potentially, to outcompete antibiotic-resistant strains from the human urinary tract. In addition, the human inoculation protocol offers unique opportunities to study host-parasite interaction in vivo in the human urinary tract. Here, we review the clinical evidence for protection using this approach as well as some molecular insights into the pathogenesis of UTI that have been gained during these studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.